Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Science ( IF 56.9 ) Pub Date : 2021-10-21 , DOI: 10.1126/science.abl8912 Kizzmekia S Corbett 1 , Matthew Gagne 1 , Danielle A Wagner 1 , Sarah O' Connell 1 , Sandeep R Narpala 1 , Dillon R Flebbe 1 , Shayne F Andrew 1 , Rachel L Davis 1 , Barbara Flynn 1 , Timothy S Johnston 1 , Christopher D Stringham 1 , Lilin Lai 2 , Daniel Valentin 3 , Alex Van Ry 3 , Zackery Flinchbaugh 3 , Anne P Werner 1 , Juan I Moliva 1 , Manjari Sriparna 1 , Sijy O'Dell 1 , Stephen D Schmidt 1 , Courtney Tucker 1 , Angela Choi 4 , Matthew Koch 4 , Kevin W Bock 5 , Mahnaz Minai 5 , Bianca M Nagata 5 , Gabriela S Alvarado 1 , Amy R Henry 1 , Farida Laboune 1 , Chaim A Schramm 1 , Yi Zhang 1 , Eun Sung Yang 1 , Lingshu Wang 1 , Misook Choe 1 , Seyhan Boyoglu-Barnum 1 , Shi Wei 1 , Evan Lamb 1 , Saule T Nurmukhambetova 1 , Samantha J Provost 1 , Mitzi M Donaldson 1 , Josue Marquez 1 , John-Paul M Todd 1 , Anthony Cook 3 , Alan Dodson 3 , Andrew Pekosz 6 , Eli Boritz 1 , Aurélie Ploquin 1 , Nicole Doria-Rose 1 , Laurent Pessaint 3 , Hanne Andersen 3 , Kathryn E Foulds 1 , John Misasi 1 , Kai Wu 4 , Andrea Carfi 4 , Martha C Nason 7 , John Mascola 1 , Ian N Moore 5 , Darin K Edwards 4 , Mark G Lewis 3 , Mehul S Suthar 2 , Mario Roederer 1 , Adrian McDermott 1 , Daniel C Douek 1 , Nancy J Sullivan 1 , Barney S Graham 1 , Robert A Seder 1
Science ( IF 56.9 ) Pub Date : 2021-10-21 , DOI: 10.1126/science.abl8912 Kizzmekia S Corbett 1 , Matthew Gagne 1 , Danielle A Wagner 1 , Sarah O' Connell 1 , Sandeep R Narpala 1 , Dillon R Flebbe 1 , Shayne F Andrew 1 , Rachel L Davis 1 , Barbara Flynn 1 , Timothy S Johnston 1 , Christopher D Stringham 1 , Lilin Lai 2 , Daniel Valentin 3 , Alex Van Ry 3 , Zackery Flinchbaugh 3 , Anne P Werner 1 , Juan I Moliva 1 , Manjari Sriparna 1 , Sijy O'Dell 1 , Stephen D Schmidt 1 , Courtney Tucker 1 , Angela Choi 4 , Matthew Koch 4 , Kevin W Bock 5 , Mahnaz Minai 5 , Bianca M Nagata 5 , Gabriela S Alvarado 1 , Amy R Henry 1 , Farida Laboune 1 , Chaim A Schramm 1 , Yi Zhang 1 , Eun Sung Yang 1 , Lingshu Wang 1 , Misook Choe 1 , Seyhan Boyoglu-Barnum 1 , Shi Wei 1 , Evan Lamb 1 , Saule T Nurmukhambetova 1 , Samantha J Provost 1 , Mitzi M Donaldson 1 , Josue Marquez 1 , John-Paul M Todd 1 , Anthony Cook 3 , Alan Dodson 3 , Andrew Pekosz 6 , Eli Boritz 1 , Aurélie Ploquin 1 , Nicole Doria-Rose 1 , Laurent Pessaint 3 , Hanne Andersen 3 , Kathryn E Foulds 1 , John Misasi 1 , Kai Wu 4 , Andrea Carfi 4 , Martha C Nason 7 , John Mascola 1 , Ian N Moore 5 , Darin K Edwards 4 , Mark G Lewis 3 , Mehul S Suthar 2 , Mario Roederer 1 , Adrian McDermott 1 , Daniel C Douek 1 , Nancy J Sullivan 1 , Barney S Graham 1 , Robert A Seder 1
Affiliation
Neutralizing antibody responses gradually wane against several variants of concern (VOC) after vaccination with the SARS-CoV-2 vaccine mRNA-1273. We evaluated the immune responses in nonhuman primates that received a primary vaccination series of mRNA-1273 and were boosted ~6 months later with either homologous mRNA-1273 or heterologous mRNA-1273.β, which encompasses the spike sequence of the B.1.351 beta (β) variant. Following boost, animals had increased neutralizing antibody responses across all VOC, which was sustained for at least 8 weeks post-boost. Nine weeks following boost, animals were challenged with the SARS-CoV-2 β variant. Viral replication was low to undetectable in bronchoalveolar lavages and significantly reduced in nasal swabs in all boosted animals suggesting booster vaccinations may be required to sustain immunity and protection.
中文翻译：
在 mRNA-1273 疫苗增强的非人类灵长类动物中对 SARS-CoV-2 β 变体的保护作用
接种 SARS-CoV-2 疫苗 mRNA-1273 后，中和抗体对几种关注变体 (VOC) 的反应逐渐减弱。我们评估了接受 mRNA-1273 初级疫苗接种系列的非人类灵长类动物的免疫反应，并在约 6 个月后用同源 mRNA-1273 或异源 mRNA-1273.β 加强免疫反应，其中包括 B.1.351 β 的尖峰序列(β) 变体。加强后，动物对所有 VOC 的中和抗体反应增加，加强后持续至少 8 周。加强后九周，动物接受了 SARS-CoV-2 β 变体的攻击。
更新日期：2021-10-22
中文翻译：
在 mRNA-1273 疫苗增强的非人类灵长类动物中对 SARS-CoV-2 β 变体的保护作用
接种 SARS-CoV-2 疫苗 mRNA-1273 后，中和抗体对几种关注变体 (VOC) 的反应逐渐减弱。我们评估了接受 mRNA-1273 初级疫苗接种系列的非人类灵长类动物的免疫反应，并在约 6 个月后用同源 mRNA-1273 或异源 mRNA-1273.β 加强免疫反应，其中包括 B.1.351 β 的尖峰序列(β) 变体。加强后，动物对所有 VOC 的中和抗体反应增加，加强后持续至少 8 周。加强后九周，动物接受了 SARS-CoV-2 β 变体的攻击。
京公网安备 11010802027423号